Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma

<div>(a) Baseline axial fused PET/CT from May 2017 showing increased FDG uptake. (b) Axial fused PET/CT from March 2019 showing resolution of increased FDG uptake.</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma 